Stevanato Group S.p.A.: Stevanato Group Reports Record 2021 Revenue of €843.9 million

Establishes Full Year 2022 Guidance Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology

Related Keywords

China ,Italy ,Indiana ,United States ,Canada ,United Kingdom ,Italian ,Franco Moro ,Franco Stevanato ,Italian Tax Agency ,Company Investor Relations ,Solutions Segment ,Company Annual Report On Form ,Development Expenses ,Exchange Commission ,Stevanato Group ,Establishes Full Year ,Full Year Highlights ,Chief Executive Officer ,Diagnostic Solutions Segment ,Executive Chairman ,European Time ,Financial Information ,Investor Relations ,Annual Report ,Marketing Expenses ,Administrative Expenses ,Constant Currency Revenue ,Adjusted Operating Profit ,Adjusted Operating Profit Margin ,Adjusted Diluted ,Capital Employed ,Free Cash ,Constant Currency ,Operating Profit ,Net Income ,Net Profit ,Financial Receivables ,New Plants ,Stevanato ,Group ,Reports ,Record ,021 ,Revenue ,Billion ,